Document is current
Any future updates will be listed below
-
Authors
von der Decken, Cay-Benedict https://orcid.org/0000-0001-9780-7174
Kleinert, Stefan https://orcid.org/0000-0002-2588-7547
Englbrecht, Matthias https://orcid.org/0000-0003-0228-7183
Karberg, Kirsten https://orcid.org/0000-0002-1362-7326
Gauler, Georg https://orcid.org/0000-0002-2132-8369
Ronneberger, Monika https://orcid.org/0009-0007-1929-8977
Rapp, Praxedis https://orcid.org/0009-0003-9257-1707
Schuch, Florian https://orcid.org/0000-0002-2543-0491
Wendler, Joerg https://orcid.org/0009-0009-4167-8989
Späthling-Mestekemper, Susanna https://orcid.org/0009-0008-8124-2111
Kuhn, Christoph https://orcid.org/0000-0002-0538-1717
Vorbrüggen, Wolfgang https://orcid.org/0000-0003-1076-5560
Welcker, Martin https://orcid.org/0000-0002-1856-3085
Bartz-Bazzanella, Peter https://orcid.org/0000-0001-8084-4497
-
Funding
Funding for this research was provided by:
RheumaDatenRhePort (RHADAR) GbR
Novartis Pharma
- License Information
-
More Information
Article History
Received: 7 January 2025
Accepted: 29 March 2025
First Online: 28 April 2025
Declarations
:
: C-BvdD received travel/meeting support from AbbVie and Galapagos/Alpha sigma. SK received grants from AbbVie, Novartis, and Sparrow, and consulting and/or speaker’s fees from AbbVie, Celgene, Chugai, Galapagos, Novartis, and Siemens Healthineers. ME received funding for the present study for data analysis from RHADAR GbR and also received consulting fees from AbbVie and RHADAR, speaker’s fees from AbbVie, Janssen-Cilag, Sanofi, and Swedish Orphan Biovitrum, and is on the advisory board of Chugai Pharma Germany. KK received speaker’s fees from AbbVie, Galapagos, Novartis, Rheumakademie, and UCB and travel/meeting support from UCB. GG received speaker’s fees from AbbVie, Galapagos, and Novartis and travel/meeting support from AbbVie and Novartis. JW received consulting and/or speaker’s fees from AbbVie, Janssen-Cilag, and Novartis. SS-M received speakers fees from AbbVie, Boehringer Ingelheim, Eli Lilly, GSK, Janssen-Cilag, Novartis, and UCB. MW received consulting and/or speaker’s fees from AbbVie, Fresenius, Galapagos, Lilly, and UCB and travel/meeting support from AbbVie, Galapagos, GSK, Lilly, and UCB. PB-B received speaker’s fees from AbbVie, Boehringer Ingelheim, Chugai/Roche, Janssen-Cilag, Novartis, Pfizer, and UCB and travel/meeting support from AbbVie. MR, PR, FS, CK, and WV have no conflicts of interest to disclose. C-BvdD, SK, KK, GG, SS-M, CK, WV, MW, and PB-B are members of RheumaDatenRhePort (RHADAR) GbR.Ethical approvalEthical approval for this study was obtained from the Ethics Committee of Ärztekammer Nordrhein (number 2021387; November 11, 2021) and the study was conducted in compliance with the Declaration of Helsinki. All patients enrolled in the study provided written informed consent.
